Methylguanine DNA Methyl Transferase (MGMT) Expression Predicts Response to Temozolamide in Patients with Digestive Neuroendocrine Tumors (NETs)

#475

Introduction: Temozolomide (TEM) is an oral drug with encouraging results in pancreatic NETs (PNETs). MGMT tumor deficiency seems to be correlated with higher treatment efficacy.

Aim(s): To assess MGMT expression and its correlation with the efficacy of TEM in pts with NETs.

Materials and methods: Inclusion of pts with well-differentiated, progressive NETs treated with TEM. Treatment efficacy was defined according to RECIST. Pts with progression or stable disease were considered non-responders. Nuclear expression of MGMT was studied by immunohistochemistry and graded according to the intensity of staining (0 to 3) and the proportion of positive cells, leading to a score comprised between 0 and 300. A score>80 was defined as high.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Hentic O, Cros J, Rebours V, Zappa M, Maire F,

Keywords: neuroendocrine tumor, treatment, temozolomide, MGMT,

To read the full abstract, please log into your ENETS Member account.